6591 RESULTS
Sort By:
In its national coverage determination, Medicare limits Aduhelm coverage to clinical trials, but OKs registry-based studies for traditionally approved anti-Aβ antibodies. This may change once new efficacy data comes out.
Eight adults who, as children, had received growth hormone from cadavers developed cognitive problems and/or AD-like pathology in midlife.
Most observational cohorts are on pause, and many clinical trials have stopped dosing. The long-term effects on the integrity of AD studies are unclear.
Months before mice develop plaques, faulty lysosomes swollen with Aβ commandeer plasma, ER, and Golgi membranes, creating toxic rosettes around the nucleus. The neurons eventually burst, leaving behind plaques.
Anti-amyloid therapy could compromise brain health, a meta-analysis claims. Others say the concern is overblown.
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
After shutting down a Phase 3 program last March, Biogen now says the futility analysis it did was incorrect, and that a new analysis of a larger dataset in fact supports filing for FDA marketing approval next year.
The indefatigable Colombian neurologist leaves behind a legacy of Alzheimer’s prevention research, which, at the time of his passing, stands on the cusp of success.
Scientists at CTAD found the Phase 3 trial well-done, the data consistent, and expect the drug to be approved. Priorities: grow the effect, understand the bleeding risk.
Using a collection of isogenic iPSC-derived neurons harboring different familial AD mutations, researchers found that, across the board, the mutations meddled with endosomes via elevated β-CTF.
A giant of basic science, Ihara biochemically characterized Aβ and tau deposits in AD brain, laying the groundwork for subsequent discoveries.
Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...
It is with deep sadness that we inform the Alzheimer research community of the passing of Anne Cataldo...
Discoverer of ApoE4 risk allele died of a heart attack.
For the first time, NIA-AA proposal bases diagnosis in living people solely on biomarkers for plaques and tangles.
No filters selected
